Icotinib is an EGFR-TKI of the first generation, which was approved for the treatment of advanced EGFR-mutated NSCLC based on the results from the ICOGEN and the CONVINCE trials.16,17 Results from the ICOGEN study indicated that icotinib was non-inferior to gefitinib in previously treated advanced NSCLC in terms of PFS (median, 4.6 months vs. 3.4 months), OS (median, 13.3 months vs. 13.9 months), and objective response rate (27.6% vs. 27.2%). Here, EGFR is linked to non-small cell lung carcinoma.